ICON plc is a global provider of clinical research and drug development services. It was founded in 1990 and is headquartered in Dublin, Ireland. The company assists pharmaceutical, biotechnology, and medical device companies in all stages of the drug development process, from early-phase clinical trials to post-approval studies.
ICON offers a comprehensive range of services that include clinical trial management, data management and analysis, laboratory testing, regulatory consulting, and patient recruitment. The company's expertise in these areas helps its clients navigate the complex regulatory landscape and accelerate the development of new therapies and medical innovations.
With a global presence in over 40 countries, ICON operates across various therapeutic areas, including oncology, cardiovascular, infectious diseases, and neurology. Its multidisciplinary teams of scientists, physicians, and regulatory experts collaborate with clients to design and execute efficient and high-quality clinical trials.
In terms of going public, ICON completed its initial public offering (IPO) in 1998. The IPO allowed the company to raise capital and expand its operations. Since then, ICON has grown both organically and through strategic acquisitions, solidifying its position as a leading provider of clinical research services.
The company's success is attributed to its commitment to scientific excellence, operational efficiency, and customer satisfaction. ICON invests significantly in research and development to enhance its capabilities and stay at the forefront of innovation in the clinical research industry. Its focus on quality, compliance, and ethical conduct has earned the trust of its clients and regulatory authorities worldwide.